|This Slide: #94 of 100|
Slide #94. Cesca Therapeutics Inc. (f/n/a ThermoGenesis Corp.) — TotipotentRX Corporation
Cesca Therapeutics Inc. (f/n/a ThermoGenesis Corp.) (KOOL)
Cesca Therapeutics Inc. (f/n/a ThermoGenesis Corp.) ("Company") (Nasdaq:KOOL) today announced that it consummated the merger with TotipotentRX Corporation ("TotipotentRX") for approximately 12,490,800 shares of the Company's common stock, as contemplated by the previously announced Agreement and Plan of Reorganization (the "Merger Agreement").
Cesca Therapeutics develops and commercializes a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics. Co. develops and supplies automation technologies for the isolation, purification and storage of stem cells for the cord blood banking industry. Through its ThermoGenesis Corp. subsidiary, Co. provides the AutoXpress® and BioArchive® platforms for automated clinical bio-banking, PXP® platform for point-of-care cell-based therapies and CAR-TXpress platform under development for bio-manufacturing for immuno-oncology applications. Co. is also developing autologous cell-based therapies that address needs in the vascular and orthopedic markets.
Open the KOOL Page at The Online Investor »
Strong Buy (4.00 out of 4)
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite